Feb 2, 2026 7:00 am EST Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Jan 29, 2026 7:00 am EST Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Jan 5, 2026 7:00 am EST Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Nov 10, 2025 4:01 pm EST Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
Nov 5, 2025 7:05 am EST Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
Nov 5, 2025 7:00 am EST Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
Oct 6, 2025 7:00 am EDT Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial